All In Biotech

Drug Trial Radar · NCT01230775

Anagrelide Retard vs. Placebo: Efficacy and Safety in "At-risk" Patients With Essential Thrombocythaemia

A Phase III, Randomized, Multicenter, Subject and Sponsor-blinded, Placebo Controlled Study to Compare the Efficacy and Safety of "Anagrelide Retard" Versus Placebo in "at Risk" Subjects With Essential Thrombocythaemia

Last checked: Nov 20, 2026Latest source record: May 26, 2016 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 146 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

146

Actual

Start

Dec 2010

Primary completion

Jan 2015

Study completion Jan 2015

Sponsor

Lead sponsor
AOP Orphan Pharmaceuticals AGIndustry
Sponsor type
Industry
First posted
Oct 29, 2010

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, outcomes assessor)
Primary purpose
Prevention
Who can join
All sexes, from 18 years, up to 60 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multicenter, phase III, randomized, subject and sponsor-blinded, placebo-controlled study to determine the treatment effect of "Anagrelide retard" in subjects with Essential Thrombocythaemia (ET) at "defined risk" (definition of risk criteria: see Inclusion Criteria Section 5.1) The study is planned as a 2-stage procedure according to Bauer and Köhne: After recruitment of 140 subjects an interim analysis with re-assessment of sample size is planned in an adaptive manner. As the confirmatory analysis will be based on a time-to-event evaluation (i.e. time to 1st clinically significant ET related event), there is no stipulated observation time identically applying for all subjects. Yet, with an interim analysis being performed after having recruited 140 subjects - which is expected to be reached after 1 year - the estimated observation time for a subject in stage I will also be about 1 year. (Details are explained in the section "Statistical Considerations"). Subjects will be randomized in a 1:1 ratio to one of the following two arms: Group A: Anagrelide retard Group B: Placebo An a priori stratification is planned for the JAK-2 mutational status. For exploratory purposes a post hoc stratification is used for obtaining covariate adjusted results, for the following other potentially predictive factors: sex, age, Factor V Leiden, and BMI. Dosing will be started with 1 tablet per day for week 1 and will be titrated up according to response (platelet reduction) to 2 tablets in week 2. Dosing may be further increased or decreased according to platelet response in week 3 and 4. However, the maximum dose is 4 tablets (=8mg) per day. After week 4, the maximum dose to achieve optimal platelet counts (\<450 G/L) should be maintained (for visit schedule see study flow chart section IV). To verify a treatment response, platelet counts must be evaluated at every visit. The platelet count values will be withheld from the subjects for the duration of stage I or stage II respectively. The subjects have to agree explicitly to this procedure by signing the Informed Consent form. This is a patient and sponsor-blinded clinical study. The trial medical is packaged in the blinded fashion to keep the patient unaware (blinded) towards the actual treatment group they were randomized to. The sponsor functions (including medical monitor, pharmacovigilance manager, clinical project manager, trial data manager and trial statistician) with stay blinded in the course of the study until the database lock. Randomization scheme will be prepared by an independent statistician (not otherwise involved in the study), and will be stored securely with no access to it by the sponsor functions mentioned above. The process of randomization (provision of the individual drug-allocation information to the subjects) will be carried out by a trained staff by Harrison, in adherence to the procedures to keep the other blinded functions unaware of this information (blinded). Unblinding envelopes, which contain the treatment code per patient number for identification of treatment in case when a safety-relevant unblinding needed, will be stored at the sponsor's site. At the end of the study, verification of the extent of maintaining the blind by checking if the envelopes have been broken, will take place and will be properly documented. If the sealed envelope will broken to provide treatment identification, the date of breaking the code, the initials of the person who broke the code and the reason will be stated on the envelope. The operational details on the blinding procedures are outlined in the relevant working guidelines (ARETA Study Working Guideline for idv staff and ARETA Study Working Guideline for Harrison, each in its current version). Investigator will not be blinded in this study, i.e. in case of a medical need individual patient management will be driven by the full knowledge of the trial related interventions. For the case, the sponsor will need to unblind a patient (e.g. due to safety reasons), the above mentioned (in this section) envelopes will be used. Only treatment naïve subjects, in respect to cytoreductive drugs with confirmed diagnosis of ET (centralized re-evaluation according to WHO, 2008; see Section 6.2.1) and assessment of JAK-2 status (centralized re-evaluation of JAK-2 status; see Section 6.2.2) will be enrolled. As described above, stage I of the study will be considered as closed as soon as 140 subjects have been recruited. The duration of stage II depends on the result of the re-assessment of sample size. Once stage I is finished, stage I subjects will enter into an extension period for a maximum of three years.

Conditions

  • Essential Thrombocythaemia

Interventions

  • Anagrelide retardDrug

    Week 1: 1x1 tablet/d of "Anagrelide retard" (1 tablet = 2mg; total dose = 2mg/d) will be administered in week 1. Week 2 "Anagrelide retard": Dosing will be titrated up according to response (platelet reduction) to 4 mg/day (=2x1 tablet) in week 2. Week 3 - Week 4 "Anagrelide retard" In week 3 and 4, dose will either be increased or decreased to maintain platelets in the normal or close to normal range. The maximum dose is 4 tablets (=8mg Anagrelide) per day. Maintenance Phase "Anagrelide retard" During maintenance phase (month 2 - month 12) doses of treatment are adjusted at the highest tolerated level which is able to maintain the platelet count within the normal range.

  • PlaceboDrug

    Week 1: 1. x1 tablet/d of placebo will be administered in week 1. Week 2 Placebo: 2. x1 tablet/d of placebo will be administered in week 2. Week 3 - Week 4 Placebo: In week 3 and week 4 the maximum dose is 4 tablets per day. Placebo: In order to guarantee blinding of subjects the number of placebo tablets to be taken by the subject will vary during maintenance period: Month 2 - month 3: 2x1 tablet/d Month 3 - month 6: 3x1 tablet/d Month 6 - month 9: 4x1 tablet/d Month 9 - month 12: 4x1 tablet/

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Time to 1st clinically significant ET related eventTime frame: beginning 2012

Locations

37 sites in 9 countries. Site status is shown where the registry gives one.

  • Uniklinik Innsbruck

    Innsbruck, Austria

  • Universitätsklinik für Innere Medizin III, Universitätsklinikum Salzburg

    Salzburg, Austria

  • Hanusch Krankenhaus

    Vienna, Austria

  • Sozialmedizinisches Zentrum Ost

    Vienna, Austria

  • Uniklinik für Innere Medizin I

    Vienna, Austria

  • University Multiprofile Hospital for Active Treatment "Dr Georgi Stranski"

    Pleven, Bulgaria

  • University Multiprofile Hospital for Active Treatment "Sveti Georgi"

    Plovdiv, Bulgaria

  • Multiprofile Hospital for Active Treatment, "Tokuda Hospital Sofia"

    Sofia, Bulgaria

  • National Specialized Hospital for Active Treatment of Hematological Diseases

    Sofia, Bulgaria

  • SHAT "Joan Pavel"

    Sofia, Bulgaria

  • Clinical Hospital Dubrava

    Zagreb, Croatia

  • Kauno Medicinos Universiteto Klinikos

    Kaunas, Lithuania

  • Klaipeda Hospital

    Klaipėda, Lithuania

  • Uniwersyteckie Centrum Kliniczne

    Gdansk, Poland

  • SP Szpital Kliniczny im. A. Mieleckiego

    Katowice, Poland

  • Wojewódzki Szpital Specjalistyczny

    Rzeszów, Poland

  • Specjalistyczny Szpital Miejski

    Torùn, Poland

  • Klinika Hematologiczna, Instytut Hematologii i Transfuzjologii

    Warsaw, Poland

  • Samodzielny Publiczny Centralny Szpital

    Warsaw, Poland

  • Clinical County Hospital "Dr. Constantin Opris"

    Baia Mare, Romania

  • "Coltea" Clinic Hospital

    Bucharest, Romania

  • "Fundeni" Clinical Institute

    Bucharest, Romania

  • University Emergency Hospital

    Bucharest, Romania

  • Emergency County Clinic Hospital

    Sibiu, Romania

  • Emergency County Hospital Târgu Mureș

    Târgu Mureş, Romania

  • State Medical Institution Territorial Clinical

    Krasnodar, Russia

  • Haematology Research Center of RAMS

    Moscow, Russia

  • Leningrad Regional Clinical Hospital

    Saint Petersburg, Russia

  • Russian scientific Research Institute for Hematology and Transfusiology

    Saint Petersburg, Russia

  • Saint Petersburg State Institution of Healthcare

    Saint Petersburg, Russia

  • Yaroslavl Regional Clinical Hospital

    Yaroslavl, Russia

  • University Hospital Bratislava

    Bratislava, Slovakia

  • Institute of Urgent and Recovery Surgery n.a.

    Donetsk, Ukraine

  • Kmelnitskiy Regional Hospital

    Khmelnitskiy, Ukraine

  • Institute of Haematology and Transfusiology

    Kiev, Ukraine

  • Scientific Center of Radiation Medicine AMS of Ukraine

    Kiev, Ukraine

  • Lviv Blood Pathology Institute

    Lviv, Ukraine

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.